Skip to main content
SpringerLink
Log in

Putting More Weight on Obesity Trials in Heart Failure

  • Review
  • Published:
Current Heart Failure Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To review ongoing and planned clinical trials of weight loss among individuals with or at high risk of heart failure.

Recent Findings

Intentional weight loss via semaglutide among persons with heart failure and preserved ejection fraction and obesity significantly improves weight loss and health status as assessed by the KCCQ-CSS score and is associated with improvements in 6-min walk test.

Summary

Ongoing and planned trials will explore the role of intentional weight loss with treatments such as semaglutide or tirzepatide for individuals with heart failure across the entire ejection fraction spectrum.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. The GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 Years. N Engl J Med. 2017;377:13–27.

  2. Sarma S, Sockalingam S, Dash S. Obesity as a multisystem disease: trends in obesity rates and obesity-related complications. Diabetes Obes Metab. 2021;23(Suppl 1):3–16.

    Article  CAS  PubMed  Google Scholar 

  3. Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity among adults and youth: United States, 2015–2016. NCHSData Brief. 2017;288:8.

    Google Scholar 

  4. Sattar N, McMurray J, Borén J, Rawshani A, Omerovic E, Berg N, et al. Twenty years of cardiovascular complications and risk factors in patients with type 2 diabetes: a nationwide Swedish cohort study. Circulation. 2023;147:1872–86.

    Article  CAS  PubMed  Google Scholar 

  5. Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson A-M, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018;379:633–44.

    Article  PubMed  Google Scholar 

  6. Kenchaiah S, Pocock SJ, Wang D, Finn PV, Zornoff LAM, Skali H, et al. Body mass index and prognosis in patients with chronic heart failure. Circulation. 2007;116:627–36. Landmark paper showing that each 1 point increase in BMI is associated with a 5% increase in risk of HF for men, and 7% increase in risk for women.

    Article  PubMed  Google Scholar 

  7. Ndumele CE, Matsushita K, Lazo M, Bello N, Blumenthal RS, Gerstenblith G, et al. Obesity and subtypes of incident cardiovascular disease. J Am Heart Assoc. 2016;5:e003921.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Adamson C, Jhund PS, Docherty KF, Bělohlávek J, Chiang C-E, Diez M, et al. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. Eur J Heart Fail. 2021;23:1662–72.

    Article  CAS  PubMed  Google Scholar 

  10. Adamson C, Kondo T, Jhund P, de Boer RA, Honorio JWC, Claggett B, et al. Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J. 2022;43:4406–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Alexander JK, Amad KH, Cole VW. Observations on some clinical features of extreme obesity, with particular reference to cardiorespiratory effects. Am J Med. 1962;32:512–24.

    Article  Google Scholar 

  12. Kasper EK, Hruban RH, Baughman KL. Cardiomyopathy of obesity: a clinicopathologic evaluation of 43 obese patients with heart failure. Am J Cardiol. 1992;70:921–4.

    Article  CAS  PubMed  Google Scholar 

  13. Rabbia F, Silke B, Conterno A, Grosso T, De Vito B, Rabbone I, et al. Assessment of cardiac autonomic modulation during adolescent obesity. Obes Res. 2003;11:541–8.

    Article  PubMed  Google Scholar 

  14. Henning RJ. Obesity and obesity-induced inflammatory disease contribute to atherosclerosis: a review of the pathophysiology and treatment of obesity. Am J Cardiovasc Dis. 2021;11:504–29.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Alpert MA, Lavie CJ, Agrawal H, Aggarwal KB, Kumar SA. Obesity and heart failure: epidemiology, pathophysiology, clinical manifestations, and management. Transl Res. 2014;164:345–56.

    Article  CAS  PubMed  Google Scholar 

  16. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389:1069–84. STEP HFpEF is the first randomized clinical trial to show that intentional weight loss (via semaglutide) results in significant improvement in clinical status for patients with heart failure and preserved ejection fraction.

    Article  CAS  PubMed  Google Scholar 

  17. The LOOK AHEAD Investigators. Cardiovascular effectsof intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369:145–54.

    Article  Google Scholar 

  18. Novo Nordisk. SELECT - Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity [Internet]. 2023. https://clinicaltrials.gov/ct2/show/NCT03574597. Accessed 6 Apr 2023.

  19. Eli Lilly and Company. A study of tirzepatide (LY3298176) on the reduction on morbidity and mortality in adults with obesity (SURMOUNT-MMO) [Internet]. https://clinicaltrials.gov/study/NCT05556512. Accessed 8 Jul 2023.

  20. Eli Lilly and Company. A study of tirzepatide (LY3298176) in participants with heart failure with preserved ejection fraction and obesity [Internet]. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04847557. Accessed 22 Jul 2023.

  21. Hamilton Health Sciences Corporation. Bariatric surgery for the reduction of cardiovascular events feasibility randomized controlled trial (BRAVE) [Internet]. Report No.: NCT04226664. 2022. https://clinicaltrials.gov/study/NCT04226664.

  22. Sharma A, Lavie CJ, Borer JS, Vallakati A, Goel S, Lopez-Jimenez F, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 2015;115:1428–34.

    Article  PubMed  Google Scholar 

  23. Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–3.

    Article  CAS  PubMed  Google Scholar 

  24. Sperrin M, Candlish J, Badrick E, Renehan A, Buchan I. Collider bias is only a partial explanation for the obesity paradox. Epidemiology. 2016;27:525–30.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Butt JH, Petrie MC, Jhund PS, Sattar N, Desai AS, Køber L, et al. Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox. Eur Heart J. 2023;44:1136–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.

    Article  CAS  PubMed  Google Scholar 

  27. Butler J, Shahzeb Khan M, Lindenfeld J, Abraham WT, Savarese G, Salsali A, et al. Minimally clinically important difference in health status scores in patients with HFrEF vs HFpEF. JACC Heart Fail. 2022;10:651–61.

    Article  PubMed  Google Scholar 

  28. Borlaug BA, Kitzman DW, Davies MJ, Rasmussen S, Barros E, Butler J, et al. Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial. Nat Med. 2023;29:2358–65.

  29. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221–32.

    Article  CAS  PubMed  Google Scholar 

  30. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–16.

    Article  CAS  PubMed  Google Scholar 

  31. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44.

    Article  CAS  PubMed  Google Scholar 

  32. Lingvay I, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity (Silver Spring). 2023;31:111–22.

    Article  CAS  PubMed  Google Scholar 

  33. News Details [Internet]. Novo Nordisk. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html. Accessed 29 Aug 2023.

  34. Khan MS, Fonarow GC, McGuire DK, Hernandez AF, Vaduganathan M, Rosenstock J, et al. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. Circulation. 2020;142:1205–18.

    Article  CAS  PubMed  Google Scholar 

  35. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA. 2016;316:500–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19:69–77.

    Article  CAS  PubMed  Google Scholar 

  37. Rao VN, Fudim M, Mentz RJ, Michos ED, Felker GM. Regional adiposity and heart failure with preserved ejection fraction. Eur J Heart Fail. 2020;22:1540–50.

    Article  CAS  PubMed  Google Scholar 

  38. Sorimachi H, Obokata M, Takahashi N, Reddy YNV, Jain CC, Verbrugge FH, et al. Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction. Eur Heart J. 2020;42:1595–605.

    Article  PubMed Central  Google Scholar 

  39. Xu C, Guo Y, Zhang S, Lai Y, Huang M, Zhan R, et al. Visceral adiposity index and the risk of heart failure, late-life cardiac structure, and function in ARIC study. Eur J Prev Cardiol. 2023;30:1182–92.

    Article  PubMed  Google Scholar 

  40. Borlaug BA, Jensen MD, Kitzman DW, Lam CSP, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2022;18(18):3434–50. An excellent review of the mechanisms and pathophysiology underlying heart failure with preserved ejection fraction in patients with obesity.

    Article  Google Scholar 

  41. Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176:611–7.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Hollstein T, Schlicht K, Krause L, Hagen S, Rohmann N, Schulte DM, et al. Effect of various weight loss interventions on serum NT-proBNP concentration in severe obese subjects without clinical manifest heart failure. Sci Rep. 2021;11:10096.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Fedele D, Bicchiega V, Collo A, Barutta F, Pistone E, Gruden G, et al. Short term variation in NTproBNP after lifestyle intervention in severe obesity. PLoS ONE. 2017;12:e0181212.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Survodutide (BI 456906) [Internet]. Boehringer Ingelheim. 2023.  https://www.boehringer-ingelheim.com/survodutide-bi-456906. Accessed 29 Aug 2023.

  45. Eli Lilly and Company. A phase 2 study of once-weekly LY3437943 compared with placebo in participants who have obesity or are overweight with weight-related comorbidities [Internet]. clinicaltrials.gov. Report No.: NCT04881760. 2023. https://clinicaltrials.gov/study/NCT04881760.

  46. News details [Internet].  http://www.novonordisk.com/media/news-details.2129162.html. Accessed 1 Apr 2018.

  47. Novo Nordisk A/S. The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascular disease [Internet]. clinicaltrials.gov. Report No.: NCT05669755. 2023. https://clinicaltrials.gov/ct2/show/NCT05669755.

  48. Rivus Pharmaceuticals, Inc. Exploratory Phase 2A, double-blind, placebo-controlled, dose escalation study to determine the safety, tolerability, PD, and PK of HU6 for the Treatment of subjects with obese heart failure with preserved ejection fraction (HFpEF) [Internet]. clinicaltrials.gov. Report No.: NCT05284617. 2023. https://clinicaltrials.gov/study/NCT05284617.

  49. Amgen. A Phase 2 randomized, placebo-controlled, double-blind, dose-ranging study to evaluate the efficacy, safety, and tolerability of AMG 133 in adult subjects with overweight or obesity, with or without type 2 diabetes mellitus [Internet]. clinicaltrials.gov. Report No.: NCT05669599. https://clinicaltrials.gov/study/NCT05669599. Accessed Aug 2023.

  50. Batsis JA, Sarr MG, Collazo-Clavell ML, Thomas RJ, Romero-Corral A, Somers VK, et al. Cardiovascular risk after bariatric surgery for obesity. Am J Cardiol. 2008;102:930–7.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Doumouras AG, Wong JA, Paterson JM, Lee Y, Sivapathasundaram B, Tarride J-E, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease. Circulation. 2021;143:1468–80.

    Article  CAS  PubMed  Google Scholar 

  52. Fisher DP, Johnson E, Haneuse S, Arterburn D, Coleman KJ, O’Connor PJ, et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA. 2018;320:1570–82.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. St Clair Gibson A, Goedecke JH, Harley YX, Myers LJ, Lambert MI, Noakes TD, et al. Metabolic setpoint control mechanisms in different physiological systems at rest and during exercise. J Theor Biol. 2005;236:60–72.

    Article  CAS  PubMed  Google Scholar 

  55. Obesity: How do we treat America’s silent killer without breaking the economy? [Internet]. MedicalEconomics 2023. https://www.medicaleconomics.com/view/obesity-how-do-we-treat-america-s-silent-killer-without-breaking-the-economy-. Accessed 27 Jan 2024.

Download references

Acknowledgements

The editors would like to thank Dr. Joe Cuthbert for handling the review of this manuscript.

Funding

No funding was received for this article.

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Internal Medicine, Duke University Medical Center, Durham, NC, USA

    Josephine Harrington, G Michael Felker & Neha J. Pagidipati

  2. Duke Clinical Research Institute, 300 W. Morris St, Durham, NC, 27701, USA

    Josephine Harrington, G Michael Felker & Neha J. Pagidipati

  3. School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, UK

    Naveed Sattar

  4. Baim Institute for Clinical Research, Boston, MA, USA

    James L. Januzzi & Harriette G. C. Van Spall

  5. Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    James L. Januzzi & Carolyn S. P. Lam

  6. National Heart Centre Singapore and Duke-National University of Singapore, Bukit Merah, Singapore

    Carolyn S. P. Lam

  7. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

    Ambarish Pandey & Darren K. McGuire

  8. Research Institute of St. Joe’s, Hamilton, Canada

    Harriette G. C. Van Spall

  9. McMaster University, Hamilton, Canada

    Harriette G. C. Van Spall

  10. Parkland Health and Hospital System, Dallas, TX, USA

    Darren K. McGuire

Authors
  1. Josephine Harrington
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Naveed Sattar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G Michael Felker
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James L. Januzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Carolyn S. P. Lam
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Neha J. Pagidipati
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ambarish Pandey
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Harriette G. C. Van Spall
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Darren K. McGuire
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JH and DM prepared the initial draft: all authors contributed extensively to revisions and to subsequent iterations of the manuscript.

Corresponding author

Correspondence to Josephine Harrington.

Ethics declarations

Competing Interests

The authors declare no competing interests.

Conflict of Interest

JH has no disclosures. JLJ is a trustee of the American College of Cardiology; is a board member of Imbria Pharma; has received research support from Abbott, Applied Therapeutics, HeartFlow Inc, Innolife, and Roche Diagnostics; has consulting income from Abbott, AstraZeneca, Bayer, Beckman, Boehringer-Ingelheim, Janssen, Jana Care, Novartis, Merck, and Roche Diagnostics; and participates in clinical endpoint committees/data safety monitoring boards for Abbott, AbbVie, Bayer, CVRx, Intercept, Pfizer, and Takeda. CSPL is supported by a Clinician Scientist Award from the National Medical Research Council of Singapore; has received research support from Novo Nordisk and Roche Diagnostics; has served as a consultant or on the advisory board/steering committee/executive committee for Alleviant Medical, Allysta Pharma, AnaCardio AB, Applied Therapeutics, AstraZeneca, Bayer, Biopeutics, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, CardioRenal, Cytokinetics, Darma Inc., EchoNous Inc, Eli Lilly, Impulse Dynamics, Intellia Therapeutics, Ionis Pharmaceutical, Janssen Research & Development LLC, Medscape/WebMD Global LLC, Merck, Novartis, Novo Nordisk, ProSciento Inc, Quidel Corporation, Radcliffe Group Ltd., Recardio Inc, ReCor Medical, Roche Diagnostics, Sanofi, Siemens Healthcare Diagnostics, and Us2.ai; and serves as co-founder and non-executive director of Us2.ai. HVS was funded by the Canadian Institutes of Health Research. GMF has received research grants from NHLBI, American Heart Association, Amgen, Bayer, BMS, Merck, Cytokinetics, and CSL-Behring; has acted as a consultant to Novartis, Amgen, BMS, Cytokinetics, Medtronic, Cardionomic, Boehringer-Ingelheim, American Regent, Abbott, Astra-Zeneca, Reprieve, Myovant, Sequana, Windtree Therapeutics, and Whiteswell; and has served on clinical endpoint committees/data safety monitoring boards for Amgen, Merck, Medtronic, EBR Systems, V-Wave, LivaNova, Siemens, and Rocket Pharma. NJP reports research support from Amgen, Boehringer Ingelheim, Eggland’s Best, Eli Lilly, Novartis, Novo Nordisk, and Verily Life Sciences; has served as a consultant or on an advisory panel for Bayer, Boehringer Ingelheim, CRISPR Therapeutics, Eli Lilly, Esperion, AstraZeneca, Merck, Novartis, and Novo Nordisk; is an executive committee member for trials sponsored by Novo Nordisk and Amgen on DSMBs for trials sponsored by Janssen and Novartis. NS has consulted for and/or received speaker honoraria from Abbott Laboratories, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hanmi Pharmaceuticals, Janssen, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Roche Diagnostics, and Sanofi; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche Diagnostics outside the submitted work. AP has received research support from the National Institute on Aging GEMSSTAR Grant (1R03AG067960-01), the National Institute on Minority Health and Disparities (R01MD017529), and the National Institute of Heart, Lung, and Blood Institute (R21HL169708). He has received grant funding (to the institution) from Applied Therapeutics, Gilead Sciences, Ultromics, Myovista, and Roche; has served as a consultant for and/or received honoraria outside of the present study as an advisor/consultant for Tricog Health Inc, Lilly USA, Rivus, Cytokinetics, Roche Diagnostics, Sarfez Therapeutics, Edwards Lifesciences, Merck, Bayer, Novo Nordisk, Alleviant, and Axon Therapies; and has received nonfinancial support from Pfizer and Merck. He is also a consultant for Palomarin Inc. with stocks compensation. DKM reports personal fees from Boehringer Ingelheim, Sanofi US, Merck & Co., Merck Sharp and Dohme Corp., Eli Lilly USA, Novo Nordisk, AstraZeneca, Lexicon Pharmaceuticals, Eisai, Pfizer, Metavant, Applied Therapeutics, Afimmune, Bayer, CSL Behring and Esperion; research support for Clinical Trials Leadership from Boehringer Ingelheim, Pfizer, AstraZeneca, Novo Nordisk, Esperion, Lilly USA, CSL Behring, and honoraria for consultancy from Lilly USA, Pfizer, Boehringer Ingelheim, Lexicon, Novo Nordisk, Applied Therapeutics, Altimmune, CSL Behring, Bayer, Intercept, New Amsterdam.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harrington, J., Sattar, N., Felker, G.M. et al. Putting More Weight on Obesity Trials in Heart Failure. Curr Heart Fail Rep 21, 194–202 (2024). https://doi.org/10.1007/s11897-024-00655-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11897-024-00655-z

Keywords

Search

Navigation